Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation  Daniel R Couriel, Rima M Saliba, Sergio Giralt, Issa Khouri, Borje Andersson, Marcos de Lima, Chitra Hosing, Paolo Anderlini, Michelle Donato, Karen Cleary, James Gajewski, Joyce Neumann, Cindy Ippoliti, Gabriela Rondon, Agueda Cohen, Richard Champlin  Biology of Blood and Marrow Transplantation  Volume 10, Issue 3, Pages 178-185 (March 2004) DOI: 10.1016/j.bbmt.2003.10.006

Figure 1 Cumulative incidence of acute GVHD. Patients receiving nonmyeloablative regiments were compared with those receiving myeloablative regimens. Progression of malignancy, immunosuppression withdrawal, donor lymphocyte infusion, and death without GVHD were considered competing risks. Biology of Blood and Marrow Transplantation 2004 10, 178-185DOI: (10.1016/j.bbmt.2003.10.006)

Figure 2 Cumulative incidence of chronic GVHD. Patients receiving nonmyeloablative regimens were compared with those receiving busulfan/cyclophosphamide and fludarabine/melphalan. Progression of malignancy, immunosuppression withdrawal, donor lymphocyte infusion, and death without GVHD were considered competing risks. Biology of Blood and Marrow Transplantation 2004 10, 178-185DOI: (10.1016/j.bbmt.2003.10.006)

Figure 3 Cumulative incidence of all GVHD. Patients receiving nonmyeloablative (NMA) regimens were compared with those receiving myeloablative (MA) regimens. Only mortality was considered a competing risk. Patients undergoing immunosuppression withdrawal, DLI, or both were included in both the NMA (n = 44) and MA (n = 29) groups. Biology of Blood and Marrow Transplantation 2004 10, 178-185DOI: (10.1016/j.bbmt.2003.10.006)